

✓A leading precision medicine company, ArteraAI develops AI-enabled tests to help personalize therapy for cancer patients.


We're heading to #SUO2026! The Artera team looks forward to connecting with the urologic oncology community and discussing how AI-powered biomarkers can help inform personalized prostate cancer care. #ArteraOnTheGo

Big news! The ArteraAI Prostate Test (Post-RP) is now included in the @NCCN Guidelines for Prostate Cancer as a risk stratification tool following biochemical recurrence after surgery. Another milestone in personalized care. buff.ly/BW4i5xo

The #NCCN #prostatecancer guidelines now include the ArteraAI Prostate Test (Post-RP), an AI-based digital pathology tool, for risk stratification in biochemical recurrence after radical prostatectomy. 🔗 targetedonc.com/view/arteraa…

The Artera team is heading to the Puerto Rico Urological Association Annual Meeting to connect with colleagues and discuss advances in personalized prostate cancer care. See you there! #ArteraOnTheGo

In @UrologyTimes, Dr. Daniel Spratt discusses new STAR-CAP benchmarking findings and what they mean for evaluating multimodal AI. Watch the full series: buff.ly/Kd4ylR2

That's a wrap on #LUGPA2026! Thank you to everyone who connected with the Artera team in Chicago. We enjoyed the conversations and the opportunity to exchange ideas with the urology community.

The future of AI in cancer care depends on more than better algorithms. In @TheAIJournal1, Artera explores why rigorous validation, real-world reliability, and strong clinical evidence are essential to responsible AI adoption. Read the full article: buff.ly/RDYa0b7

What could precision medicine look like in five years? On PathPulse, Artera's Laura Chang shares her vision for expanding AI-powered biomarkers across diseases and making them more accessible worldwide. Watch the interview: buff.ly/Gnc0ySa @LumeaDigital

The Artera team is heading to the @ChiUroSociety November 4 meeting! We look forward to connecting with colleagues and discussing advances in prostate cancer care. See you there! #ArteraOnTheGo

Artera has received @Frost_Sullivan's 2026 Technology Innovation Leadership Award for AI-Powered Breast Cancer Stratification! This #BreastCancerAwarenessMonth, we're proud to advance AI-driven insights for more personalized care.

Patient advocacy has helped shape precision medicine. This #BreastCancerAwarenessMonth, Artera's Calvin Chao explores its impact on cancer care and why inclusivity matters as AI advances. Read more: buff.ly/gW5MIvx

We're heading to #LUGPA26! The Artera team looks forward to connecting with the urology community and discussing how AI-powered biomarkers can help inform personalized prostate cancer care. See you there! @UrologyUS

That's a wrap on #PathVisions26! Thank you to everyone who connected with the Artera team. We enjoyed exchanging ideas and discussing the future of digital pathology and AI-powered diagnostics.

AI biomarkers should work across the diverse populations they're intended to serve. New data presented at #ASTRO2026 found similar performance of the ArteraAI prostate biomarker across racial and age subgroups studied, with no evidence of bias. Read more: buff.ly/KbGFjsM

We’re heading to the @AmerUrological Western Section Annual Meeting! The Artera team looks forward to connecting with the urology community and discussing the role of AI-powered biomarkers in #ProstateCancer care. Attending? Come say hello! 👋 #ArteraOnTheGo